IN2014CN03919A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03919A
IN2014CN03919A IN3919CHN2014A IN2014CN03919A IN 2014CN03919 A IN2014CN03919 A IN 2014CN03919A IN 3919CHN2014 A IN3919CHN2014 A IN 3919CHN2014A IN 2014CN03919 A IN2014CN03919 A IN 2014CN03919A
Authority
IN
India
Prior art keywords
receptors
pharmaceutical compositions
relates
mineralocorticoid
glucocorticoid
Prior art date
Application number
Other languages
English (en)
Inventor
Jeffrey L Edelman
Alissar Nehme
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47179019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN03919(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014CN03919A publication Critical patent/IN2014CN03919A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN3919CHN2014 2011-11-11 2012-11-09 IN2014CN03919A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558775P 2011-11-11 2011-11-11
PCT/US2012/064296 WO2013071010A1 (en) 2011-11-11 2012-11-09 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11ß-17-21-TRIOL-3,20-DIONE DERIVATIVES

Publications (1)

Publication Number Publication Date
IN2014CN03919A true IN2014CN03919A (he) 2015-09-04

Family

ID=47179019

Family Applications (2)

Application Number Title Priority Date Filing Date
IN3903CHN2014 IN2014CN03903A (he) 2011-11-11 2012-11-09
IN3919CHN2014 IN2014CN03919A (he) 2011-11-11 2012-11-09

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN3903CHN2014 IN2014CN03903A (he) 2011-11-11 2012-11-09

Country Status (24)

Country Link
US (7) US8906892B2 (he)
EP (2) EP2776040B1 (he)
JP (2) JP6158201B2 (he)
KR (2) KR102049615B1 (he)
CN (2) CN104185472B (he)
AR (1) AR088846A1 (he)
AU (3) AU2012335590B2 (he)
BR (2) BR112014011341A2 (he)
CA (3) CA2855290C (he)
CL (2) CL2014001243A1 (he)
CO (2) CO6970598A2 (he)
ES (1) ES2806603T3 (he)
HK (2) HK1200367A1 (he)
IL (2) IL232534A0 (he)
IN (2) IN2014CN03903A (he)
MX (3) MX365859B (he)
MY (2) MY182222A (he)
PH (2) PH12014501078B1 (he)
RU (2) RU2688159C2 (he)
SG (3) SG11201402247PA (he)
TW (1) TWI584809B (he)
UA (2) UA116622C2 (he)
WO (2) WO2013071009A1 (he)
ZA (2) ZA201403430B (he)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
KR20160098338A (ko) * 2013-12-13 2016-08-18 알러간, 인코포레이티드 코르티솔 17-알파-벤조에이트의 다형성 및 비결정성 형태들, 및 그 조제 방법들 및 용도
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
RU2746083C2 (ru) 2015-03-05 2021-04-06 Аллерган, Инк. Самоэмульгирующиеся системы доставки лекарств (sedds) для доставки офтальмологического лекарства
WO2018053321A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (he) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
US3484436A (en) * 1967-09-07 1969-12-16 Syntex Corp Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids
GB1227992A (he) * 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3693032A (en) 1971-04-23 1972-09-19 Ibm Antisaturation technique for ttl circuits
US3984544A (en) * 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS60994B2 (ja) * 1976-07-26 1985-01-11 大正製薬株式会社 プレグナン系化合物の17α―エステル類の製造法
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
MXPA02003731A (es) * 1999-10-15 2003-12-11 Leo Pharm Prod Ltd Derivados novedosos de acido fusidico.
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
US20040097574A1 (en) * 2002-08-29 2004-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2005008596A (ja) * 2003-06-20 2005-01-13 Kobayashi Pharmaceut Co Ltd 眼科用組成物
DK1755616T3 (da) 2004-04-08 2013-11-25 Eye Co Pty Ltd Behandling af ekssudativ retinopati med mineralkortikoider
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
ES2399976T3 (es) * 2006-06-01 2013-04-04 Novagali Pharma S.A. Uso de profármacos para la administración intravítrea ocular
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2009053880A (ja) 2007-08-27 2009-03-12 Sony Broadband Solution Corp 情報処理装置、ならびにcpuユニット
MX2010007023A (es) * 2007-12-21 2010-09-30 Schering Corp Agonistas del receptor glucocorticoide sustituido de c20-c21.
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
UA116622C2 (uk) * 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей

Also Published As

Publication number Publication date
IN2014CN03903A (he) 2015-10-16
HK1200367A1 (en) 2015-08-07
UA111867C2 (uk) 2016-06-24
US10493082B2 (en) 2019-12-03
CN104185472A (zh) 2014-12-03
US20180147217A1 (en) 2018-05-31
MX2014005678A (es) 2014-12-10
AU2018200436A1 (en) 2018-02-08
CN104203247B (zh) 2017-06-06
AU2012335589A1 (en) 2014-05-29
JP2014533274A (ja) 2014-12-11
EP2776041A1 (en) 2014-09-17
MX365859B (es) 2019-06-18
SG11201402247PA (en) 2014-06-27
ZA201403430B (en) 2016-05-25
WO2013071010A1 (en) 2013-05-16
US8865691B2 (en) 2014-10-21
TW201325596A (zh) 2013-07-01
CA2855290A1 (en) 2013-05-16
US10188667B2 (en) 2019-01-29
CL2014001243A1 (es) 2014-11-28
CO6970598A2 (es) 2014-06-13
NZ624920A (en) 2017-06-30
RU2014123472A (ru) 2015-12-20
PH12014501078A1 (en) 2014-07-28
US20190365786A1 (en) 2019-12-05
US20150005519A1 (en) 2015-01-01
US20130123223A1 (en) 2013-05-16
RU2683775C2 (ru) 2019-04-02
RU2014123471A (ru) 2015-12-20
JP2014533275A (ja) 2014-12-11
PH12014501079B1 (en) 2014-07-28
SG10201603766PA (en) 2016-07-28
CA2991883C (en) 2020-03-10
AU2012335590A1 (en) 2014-05-29
CA2855929C (en) 2018-03-27
JP6158201B2 (ja) 2017-07-05
MX363669B (es) 2019-03-29
US9717743B2 (en) 2017-08-01
BR112014011333B1 (pt) 2020-04-28
MX2014005679A (es) 2014-12-10
TWI584809B (zh) 2017-06-01
UA116622C2 (uk) 2018-04-25
BR112014011341A2 (pt) 2017-05-02
CA2855929A1 (en) 2013-05-16
ES2806603T3 (es) 2021-02-18
KR102049615B1 (ko) 2019-11-28
ZA201403431B (en) 2016-05-25
CN104185472B (zh) 2017-06-13
BR112014011333A2 (pt) 2017-05-02
IL232535B (he) 2019-09-26
IL232534A0 (he) 2014-06-30
WO2013071009A1 (en) 2013-05-16
US20150057258A1 (en) 2015-02-26
CO6970609A2 (es) 2014-06-13
MX2019006877A (es) 2019-08-22
CN104203247A (zh) 2014-12-10
JP6216719B2 (ja) 2017-10-18
PH12014501079A1 (en) 2014-07-28
PH12014501078B1 (en) 2014-07-28
CL2014001244A1 (es) 2014-11-14
MY182222A (en) 2021-01-18
US9433631B2 (en) 2016-09-06
SG11201402225RA (en) 2014-06-27
AU2018200436B2 (en) 2019-10-24
KR20140095549A (ko) 2014-08-01
AU2012335590B2 (en) 2017-10-19
KR20140095548A (ko) 2014-08-01
EP2776040B1 (en) 2020-04-22
MY172227A (en) 2019-11-18
HK1200366A1 (en) 2015-08-07
NZ624919A (en) 2016-10-28
RU2688159C2 (ru) 2019-05-20
EP2776040A1 (en) 2014-09-17
IL232535A0 (he) 2014-06-30
AU2012335589B2 (en) 2017-08-31
CA2855290C (en) 2017-02-28
US8906892B2 (en) 2014-12-09
AR088846A1 (es) 2014-07-10
CA2991883A1 (en) 2013-05-16
US20130123226A1 (en) 2013-05-16
US20170182062A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IN2014CN03919A (he)
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PH12015500491A1 (en) C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MY162689A (en) Oxazoline and isoxazoline derivatives as crac modulators
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
WO2013038195A3 (en) Pharmaceutical nanoparticle compositions
IN2013MU02370A (he)
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
TN2011000523A1 (en) Chromenone derivatives as trpv3 antagonists
TN2011000518A1 (en) Fused imidazole carboxamides as trpv3 modulators
TN2011000520A1 (en) Chromane derivatives as trpv3 modulators
TN2011000517A1 (en) Fused pyrimidineone compounds as trpv3 modulators